CVS Has Rallied 65% in Three Years. The Valuation Debate Is Getting Harder

CVS Health’s 64.8% three-year return makes the valuation debate more complicated than a simple bargain call. The stock has already recovered substantially, so new buyers need to decide whether the remaining upside comes from better earnings or from investors simply paying a higher multiple.

At roughly $96.74 in the cited analysis, CVS traded near the healthcare industry’s earnings multiple and above the peer-group figure referenced in the source. A mixed value score also suggested the shares were neither obviously cheap nor clearly stretched.

That puts the focus back on fundamentals. The most important variable is still Aetna’s medical-cost trajectory. If pricing and benefit design restore insurance margins, the company’s other assets — pharmacy, benefits and care delivery — can support a stronger earnings base. If elevated utilization persists, the apparent discount can prove less attractive than it looks.

A strong past return is not an argument against further gains, but it does raise the burden of proof. Future upside increasingly needs to come from recurring earnings and free cash flow rather than a simple recovery in sentiment. For CVS, the next leg is about execution, not just valuation.

The 65% return also changes how investors should think about downside protection. A stock that has already rerated has less valuation cushion if earnings disappoint, even when it still appears inexpensive on some measures.

CVS’s free cash flow remains important because it supports debt reduction and potential shareholder returns. Strong cash generation can help the company absorb volatility in the insurance business without weakening strategic flexibility.

The mixed valuation signals in the source therefore make sense. CVS can still be undervalued if insurance margins normalize and the integrated platform produces stable cash flow, but the easy part of the recovery trade may already be behind it. New buyers are effectively making a forward-looking call on execution rather than simply buying a stock that has been left for dead.

Debt and capital allocation also influence the valuation case. CVS has used substantial capital to build its integrated health platform, so investors need confidence that cash generation remains sufficient to support the balance sheet while funding strategic priorities.

A stronger insurance outlook would give management more freedom around buybacks or other shareholder returns. Until then, preserving flexibility may be more valuable than aggressively repurchasing stock. The investment case is therefore tied not only to the earnings multiple but also to how management uses cash. After a large share-price recovery, disciplined capital allocation becomes an increasingly important source of upside.

The peer comparison in the source also matters because valuation should be relative as well as absolute. If CVS trades near the industry multiple despite carrying more operating complexity, investors need a reason to believe that complexity will eventually produce superior returns. The integrated model can justify a premium only if it improves retention, lowers costs or strengthens cash generation. Otherwise, the structure may deserve a discount. That makes upcoming evidence from Aetna and the health-services businesses especially important. The market already knows CVS has scale; it now wants proof that scale creates better economics.

The next catalyst is likely to be evidence that insurance profitability is improving without sacrificing growth elsewhere. If that appears alongside resilient cash flow, the stock can still have room to rerate even after its strong three-year performance.

If those elements align, the shares can still create value even after a large rebound.